| COMMON STOCK WARRANTS |
Note
8 - Common Stock Warrants
COMMON
STOCK WARRANTS
A
summary of the Company’s warrant issuance activity and related information for the three months ended March 31, 2022
and 2021 is as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS
| |
|
Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life |
|
| Outstanding and exercisable at December 31, 2020 |
|
|
413,423,972 |
|
|
$ |
0.02 |
|
|
|
10.30 |
|
| Expired |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Outstanding and exercisable at March 31, 2021 |
|
|
413,423,972 |
|
|
$ |
0.10 |
|
|
|
9.24 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at December 31, 2021 |
|
|
406,301,497 |
|
|
|
0.04 |
|
|
|
8.17 |
|
Expired |
|
|
(20,411,346 |
) |
|
|
0.33 |
|
|
|
- |
|
| Exercised |
|
|
(83,579,296 |
) |
|
|
0.01 |
|
|
|
- |
|
| Granted |
|
|
84,579,296 |
|
|
|
0.01 |
|
|
|
4.88 |
|
| Outstanding and exercisable at March 31, 2022 |
|
|
386,890,151 |
|
|
$ |
0.02 |
|
|
|
7.57 |
|
The
fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes valuation technique to value each of
the warrants as of their respective issue dates are as follows:
SCHEDULE
OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE
| Event Description |
|
Date |
|
|
Number of Warrants |
|
|
H-CYTE Stock Price |
|
|
Exercise Price of Warrant |
|
|
Grant Date Fair Value |
|
|
Life of Warrant |
|
|
Risk Free Rate of Return (%) |
|
|
Annualized Volatility Rate (%) |
|
| Granted for inducement agreement |
|
|
1/19/2022 |
|
|
|
3,732,289 |
|
|
$ |
0.06 |
|
|
$ |
0.014 |
|
|
$ |
0.062 |
|
|
|
5
years |
|
|
|
1.62 |
|
|
|
187.79 |
|
| Granted for inducement agreement |
|
|
1/20/2022 |
|
|
|
372,289 |
|
|
$ |
0.07 |
|
|
$ |
0.014 |
|
|
$ |
0.064 |
|
|
|
5
years |
|
|
|
1.62 |
|
|
|
187.85 |
|
| Granted for inducement agreement |
|
|
1/20/2022 |
|
|
|
187,201 |
|
|
$ |
0.07 |
|
|
$ |
0.014 |
|
|
$ |
0.064 |
|
|
|
5
years |
|
|
|
1.62 |
|
|
|
187.85 |
|
| Granted for inducement agreement |
|
|
1/24/2022 |
|
|
|
374,403 |
|
|
$ |
0.05 |
|
|
$ |
0.014 |
|
|
$ |
0.047 |
|
|
|
5
years |
|
|
|
1.53 |
|
|
|
188.01 |
|
| Granted for inducement agreement |
|
|
1/25/2022 |
|
|
|
3,744,031 |
|
|
$ |
0.05 |
|
|
$ |
0.014 |
|
|
$ |
0.048 |
|
|
|
5
years |
|
|
|
1.56 |
|
|
|
188.00 |
|
| Granted for inducement agreement |
|
|
2/02/2022 |
|
|
|
3,740,509 |
|
|
$ |
0.05 |
|
|
$ |
0.014 |
|
|
$ |
0.044 |
|
|
|
5
years |
|
|
|
1.60 |
|
|
|
188.25 |
|
| Granted for inducement agreement |
|
|
2/04/2022 |
|
|
|
6,934,785 |
|
|
$ |
0.04 |
|
|
$ |
0.014 |
|
|
$ |
0.043 |
|
|
|
5
years |
|
|
|
1.78 |
|
|
|
188.33 |
|
| Granted for inducement agreement |
|
|
2/04/2022 |
|
|
|
13,869,643 |
|
|
$ |
0.04 |
|
|
$ |
0.014 |
|
|
$ |
0.043 |
|
|
|
5
years |
|
|
|
1.78 |
|
|
|
188.33 |
|
| Granted for services provided |
|
|
2/09/2022 |
|
|
|
1,000,000 |
|
|
$ |
0.03 |
|
|
$ |
0.014 |
|
|
$ |
0.031 |
|
|
|
5 years |
|
|
|
1.82 |
|
|
|
188.69 |
|
| Granted for inducement agreement |
|
|
2/22/2022 |
|
|
|
41,608,884 |
|
|
$ |
0.03 |
|
|
$ |
0.014 |
|
|
$ |
0.032 |
|
|
|
5
years |
|
|
|
1.85 |
|
|
|
188.59 |
|
| Granted for inducement agreement |
|
|
2/22/2022 |
|
|
|
693,477 |
|
|
$ |
0.03 |
|
|
$ |
0.014 |
|
|
$ |
0.032 |
|
|
|
5
years |
|
|
|
1.85 |
|
|
|
188.59 |
|
| Granted for inducement agreement |
|
|
3/21/2022 |
|
|
|
8,321,785 |
|
|
$ |
0.03 |
|
|
$ |
0.014 |
|
|
$ |
0.027 |
|
|
|
5
years |
|
|
|
2.33 |
|
|
|
194.01 |
|
The
fair value of warrants issued during the three months ended March 31, 2022 totaled approximately $3,000,000 which is included in inducement
expense. The methods described above may produce
a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the
Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies
or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the
reporting date.
|